Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Lymphoid 3Tumor-Agnostic 2Plasma cell 2Other hematologic neoplasm 2Myeloid 2Sarcoma 1Genitourinary 1Gastrointestinal 1Classical hematology 1CNS 1Breast 1

Conditions

Myelodysplastic Syndromes 13Leukemia, Myeloid, Acute 11Leukemia 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Lymphocytic, Chronic, B-Cell 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 4Multiple Myeloma 4Lymphoma 4Primary Myelofibrosis 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Leukemia, Myelomonocytic, Chronic 3Hodgkin Disease 3Congenital Abnormalities 3Anemia, Refractory, with Excess of Blasts 3Neoplasm Metastasis 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Hematologic Neoplasms 2Thrombocytosis 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

venetoclax 2ruxolitinib 2fludarabine phosphate 2Sirolimus 2Leucovorin 2Immunoglobulin G 2Doxorubicin 2Disulfides 2Cyclophosphamide 2Bortezomib 2Bevacizumab 2Azacitidine 2vactosertib 1trametinib 1temsirolimus 1sargramostim 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1hydrocortisone sodium phosphate 1fludarabine 1enzalutamide 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Bortezomib × Myeloid × Clear all
NCT00720785 2026-05-07

Natural Killer Cells and Bortezomib to Treat Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
35 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Neoplasm Metastasis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡